Browse the evidence

GABA signaling can induce the transdifferentiation of alpha cells into beta-like cells, potentially reversing chemically induced diabetes in vivo.

There is experimental evidence that GABA, a neurotransmitter, might help convert alpha cells (which raise blood sugar) into beta-like cells (which lower blood sugar) in diabetic mice. However, the paper also notes that other studies found no such regeneration with long-term GABA or artesunate administration. This remains a research area, not a current treatment option for humans.

Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.

While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.

Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.

This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

Self-administered overdose of Semaglutide (up to 8x the weekly dose) can cause multiorgan failure, including acute kidney injury, cholestatic liver dysfunction, and gastrointestinal bleeding, in patients with Type 2 Diabetes.

If you are using Semaglutide, never inject more than the prescribed weekly dose, even if you feel you need to 'catch up' or are experiencing side effects. The delivery pen allows you to inject multiple times, which can lead to life-threatening organ failure. If you feel dysphoric or suicidal, seek immediate help and do not attempt to self-medicate or overdose.

Long-term use of FDA/Health Canada-approved obesity pharmacotherapies (semaglutide, tirzepatide, liraglutide, naltrexone-bupropion, orlistat) combined with health behavior changes produces clinically meaningful weight loss and prevents weight regain upon discontinuation.

If you have obesity (BMI ≥ 30, or ≥ 27 with health issues), talk to your doctor about FDA/Health Canada-approved weight loss medications like semaglutide or tirzepatide. These work best when combined with diet and exercise changes. Crucially, these are long-term treatments; stopping them usually leads to regaining the weight, so view them as a permanent tool for managing your health, not a quick fix.

Tirzepatide (5-15 mg weekly) produces superior weight loss compared to semaglutide and placebo in adults with obesity, with dose-dependent efficacy.

Tirzepatide is a weekly injection that can lead to significant weight loss (up to ~21% in trials). It works by targeting two hormones (GIP and GLP-1). Side effects like nausea are common but often temporary. It is approved for adults with obesity or overweight with health issues.

Injectable semaglutide 2.4 mg once weekly produces significant weight loss (mean 15.2% over 104 weeks) and improves cardiometabolic risk factors in adults with obesity.

If you have obesity and struggle to lose weight through diet and exercise alone, ask your doctor about injectable semaglutide (2.4 mg once weekly). It is clinically proven to help you lose an average of 15% of your body weight over two years and improves heart health markers. Be prepared for a slow start to minimize stomach upset, and stick with it as the benefits are significant.

Testosterone therapy in older men with low testosterone and symptoms improves sexual function, anemia, and bone mineral density, and prevents type 2 diabetes in high-risk men, while demonstrating cardiovascular safety in large RCTs.

If you are an older man with low testosterone and symptoms, testosterone therapy can improve sexual function, blood counts, and bone density. For those at high risk of diabetes, it significantly reduces that risk. Large recent studies confirm it is safe for the heart and prostate, so discuss this with your doctor if you meet the criteria.

Obesity pharmacotherapy reduces the risk of major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and BMI ≥ 27, independent of diabetes status.

If you have heart disease and are overweight (BMI ≥ 27), ask your doctor about semaglutide (Wegovy). It has been proven to reduce the risk of heart attacks and strokes, in addition to helping with weight loss.

Tirzepatide facilitates significant weight loss and improves lipid profiles in individuals with spinal cord injury (SCI) who are refractory to standard dietary and exercise interventions.

If you have a spinal cord injury and have tried strict diet and exercise without success, ask your doctor about tirzepatide. It is a weekly injection that helped this patient lose 33 pounds and improve his cholesterol, even when standard lifestyle changes failed. Be aware that GI side effects are possible, though this patient tolerated them well.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce major adverse cardiovascular events (MACE) in non-diabetic adults with obesity, with benefits occurring through both weight-loss-dependent and independent mechanisms.

If you have obesity and are not diabetic, GLP-1 medications like semaglutide or liraglutide can significantly lower your risk of heart attack, stroke, and heart failure. This benefit is not just from losing weight; the drugs also directly protect your blood vessels and heart. While side effects like nausea are common, they are usually manageable with slow dose increases and dietary changes. For those who dislike injections, oral versions are also effective.

Tirzepatide (10-15 mg weekly) produces significantly greater total weight loss (-20.2%) compared to Semaglutide (1.7-2.4 mg weekly, -13.7%) in obese patients, as demonstrated in the SURMOUNT-5 trial.

If you are struggling with obesity and other medications have failed, Tirzepatide (10-15 mg weekly) offers superior weight loss compared to Semaglutide. Discuss this dual-agonist option with your doctor, especially if you have not achieved sufficient weight loss with other GLP-1 treatments.

Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) reduce HbA1c, fasting plasma glucose, and body weight in Type 2 Diabetic athletes, but pose risks of hypovolemia, dehydration, and euglycemic DKA.

If you take SGLT2 inhibitors (like empagliflozin or dapagliflozin) for Type 2 Diabetes, you will likely lose weight and improve your blood sugar control. However, these drugs make you urinate more, which can lead to dehydration and dizziness during exercise. Drink extra water, watch for signs of low blood pressure, and be aware of the rare risk of euglycemic DKA (diabetic ketoacidosis with normal blood sugar).

Tirzepatide (5, 10, or 15 mg weekly) produces superior, dose-dependent weight loss and glycemic improvements compared to insulin and GLP-1 receptor agonists in adults with type 2 diabetes and/or obesity.

Tirzepatide is currently the most potent pharmacological therapy for weight loss and blood sugar control in type 2 diabetes and obesity, outperforming both insulin and other GLP-1 drugs. It works by mimicking two gut hormones (GIP and GLP-1) to reduce appetite and improve insulin sensitivity. While effective, it carries a higher risk of gastrointestinal side effects like nausea compared to other treatments.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss (up to 20.9% with 15 mg weekly dose) and is recommended for patients targeting 15-20% weight loss.

If you need to lose a significant amount of weight (15-20%), ask your doctor about tirzepatide. It is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1). Start at a low dose to minimize side effects, and gradually increase it over several months to find the right dose for you. It is more potent than older GLP-1 drugs.

CagriSema (semaglutide + cagrilintide) produces superior weight loss (22.7% at 68 weeks) compared to semaglutide 2.4 mg alone (16.1%) or cagrilintide alone (11.8%).

If you have obesity and need maximum weight loss, ask your doctor about CagriSema. It combines two hormones (GLP-1 and amylin) into one weekly injection. Clinical trials show it can help you lose nearly 23% of your body weight, which is more than semaglutide or tirzepatide alone. It is currently in Phase 3 trials.

Tirzepatide use, particularly with unsupervised dose escalation and caloric restriction, can cause euglycemic ketoacidosis (EKA) in non-diabetic patients.

If you are using tirzepatide, do not self-prescribe or self-escalate doses. Monitor for signs of metabolic acidosis (nausea, vomiting, abdominal pain, fatigue) especially if you are eating very little. Seek immediate medical attention if these symptoms occur, as they can signal euglycemic ketoacidosis, a rare but serious condition.

Tirzepatide treatment in premenopausal women with obesity is hypothesized to increase brown adipose tissue (BAT) volume and activity and induce white adipose tissue (WAT) browning, potentially mitigating the decline in resting energy expenditure typically associated with weight loss.

This paper outlines a clinical trial design, not a consumer guide. It hypothesizes that tirzepatide may help maintain metabolic rate during weight loss by activating brown fat and turning white fat 'beige'. The protocol involves weekly injections starting at a low dose and slowly increasing over 24 weeks, with close monitoring for side effects. No results are available yet.

SGLT2 inhibitors and GLP-1 receptor agonists provide multi-organ cardiorenal protection beyond glycemic control, with selection prioritized by phenotype (e.g., SGLT2i for heart failure/CKD, GLP-1RA for ASCVD/obesity).

If you have heart, kidney, or metabolic issues, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs protect your heart and kidneys, not just your blood sugar. Your doctor might even be able to lower your doses of other blood pressure or diabetes pills, reducing your risk of side effects like low blood sugar or dizziness.

Non-steroidal mineralocorticoid receptor antagonists (ns-MRA) like finerenone reduce cardiovascular and renal risks in T2D+CKD patients, with hyperkalemia risk manageable through monitoring.

If you have diabetes and kidney disease, ask about finerenone. It protects your heart and kidneys. Your doctor will check your potassium levels regularly to ensure it is safe for you.

Tirzepatide treatment, particularly during dose escalation, is associated with an increased risk of acute duodenal ulcer perforation in patients with pre-existing untreated Helicobacter pylori infection.

If you are taking tirzepatide and experience persistent or worsening stomach pain, nausea, or vomiting that does not resolve, do not assume it is just a normal side effect. Seek medical attention immediately, especially if you have a history of stomach issues or H. pylori. Early detection of ulcers can prevent perforation.

High-dose tirzepatide (15 mg weekly) can induce severe gastrointestinal side effects (prolonged vomiting and diarrhea) leading to profound electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia), which precipitate life-threatening ventricular fibrillation and cardiac arrest.

If you are on 15mg tirzepatide and have persistent vomiting or diarrhea, do not ignore it. Ask your doctor to check your potassium, magnesium, and calcium levels immediately. Severe GI loss can trigger dangerous heart rhythms even if you have no prior heart history.

Evidence regarding the impact of GLP-1 RAs on total shoulder arthroplasty (TSA) outcomes is limited, heterogeneous, and contradictory, with some studies showing reduced mortality and adverse events while others show increased complications.

For shoulder replacement surgery, the data on GLP-1 RAs is mixed. Some studies show benefits like lower mortality, while others show higher risks of blood clots and pneumonia. Because the evidence is weak and contradictory, your surgical team will likely evaluate your specific case carefully. Do not assume the benefits seen in hip/knee surgery apply here without explicit guidance from your surgeon.